Physician profile
Imran Ata
NPI 1366557563
$3,895.26
in general payments reported to CMS, 2019-2025
30 companies · $815 in 2025
The $815 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $160 · 2021: $96.69 · 2022: $384 · 2023: $949 · 2024: $1,234 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,997.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $856.56 | 2020-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $813.29 | 2019-2025 | |
| Amgen INC. | $334.53 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $237.36 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.79 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $171.62 | 2020-2025 | Watchman Access System, Watchman Flx |
| Baxter Healthcare | $169.01 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Pfizer INC. | $165.01 | 2019-2024 | |
| Abbott Laboratories | $118.93 | 2023-2025 | Jot Dx, Assurity, Portico |
| Astrazeneca Pharmaceuticals Lp | $117.54 | 2019-2025 | Farxiga, Lokelma |
| Actelion Pharmaceuticals US, INC. | $112.75 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $87.40 | 2023-2024 | Inpefa |
| Astellas Pharma US INC | $81.74 | 2020 | |
| Kestra Medical Technology Services, INC. | $61.70 | 2023-2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $49.07 | 2019-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $47.16 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $36.36 | 2020 | |
| Cvrx, INC. | $27.15 | 2025 | Barostim Neo System |
| Electromed, INC. | $23.51 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.59 | 2025 | |
| Novo Nordisk INC | $21.71 | 2023 | Ozempic |
| Braemar Manufacturing, LLC | $21.62 | 2019 | |
| Scpharmaceuticals INC. | $19.04 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $19.02 | 2025 | Eliquis |
| Edwards Lifesciences Corporation | $17.72 | 2019 | |
| Grifols USA, LLC | $16.52 | 2019 | |
| Cook Medical LLC | $13.84 | 2022 | |
| Philips North America LLC | $13.82 | 2020 | |
| Medtronic, INC. | $13.74 | 2021 | |
| Teleflex LLC | $13.16 | 2023 | Turnpike |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Ata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.